Reversible nonoliguric acute renal failure associated with zomepirac therapy

J. T. McCarthy, Gary Lee Schwartz, T. J. Blair, A. M. Pierides, C. J. Van den Berg

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.

Original languageEnglish (US)
Pages (from-to)351-354
Number of pages4
JournalMayo Clinic Proceedings
Volume57
Issue number6
StatePublished - 1982

Fingerprint

Acute Kidney Injury
Therapeutics
Interstitial Nephritis
Withholding Treatment
Non-Steroidal Anti-Inflammatory Agents
Chronic Renal Insufficiency
Analgesics
zomepirac
Hypertension
Kidney
Biopsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

McCarthy, J. T., Schwartz, G. L., Blair, T. J., Pierides, A. M., & Van den Berg, C. J. (1982). Reversible nonoliguric acute renal failure associated with zomepirac therapy. Mayo Clinic Proceedings, 57(6), 351-354.

Reversible nonoliguric acute renal failure associated with zomepirac therapy. / McCarthy, J. T.; Schwartz, Gary Lee; Blair, T. J.; Pierides, A. M.; Van den Berg, C. J.

In: Mayo Clinic Proceedings, Vol. 57, No. 6, 1982, p. 351-354.

Research output: Contribution to journalArticle

McCarthy, JT, Schwartz, GL, Blair, TJ, Pierides, AM & Van den Berg, CJ 1982, 'Reversible nonoliguric acute renal failure associated with zomepirac therapy', Mayo Clinic Proceedings, vol. 57, no. 6, pp. 351-354.
McCarthy JT, Schwartz GL, Blair TJ, Pierides AM, Van den Berg CJ. Reversible nonoliguric acute renal failure associated with zomepirac therapy. Mayo Clinic Proceedings. 1982;57(6):351-354.
McCarthy, J. T. ; Schwartz, Gary Lee ; Blair, T. J. ; Pierides, A. M. ; Van den Berg, C. J. / Reversible nonoliguric acute renal failure associated with zomepirac therapy. In: Mayo Clinic Proceedings. 1982 ; Vol. 57, No. 6. pp. 351-354.
@article{8567f3c9356f40f380e57c94205e3cce,
title = "Reversible nonoliguric acute renal failure associated with zomepirac therapy",
abstract = "Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.",
author = "McCarthy, {J. T.} and Schwartz, {Gary Lee} and Blair, {T. J.} and Pierides, {A. M.} and {Van den Berg}, {C. J.}",
year = "1982",
language = "English (US)",
volume = "57",
pages = "351--354",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "6",

}

TY - JOUR

T1 - Reversible nonoliguric acute renal failure associated with zomepirac therapy

AU - McCarthy, J. T.

AU - Schwartz, Gary Lee

AU - Blair, T. J.

AU - Pierides, A. M.

AU - Van den Berg, C. J.

PY - 1982

Y1 - 1982

N2 - Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.

AB - Zomepirac sodium (Zomax) is a nonsteroidal anti-inflammatory agent with analgesic properties which was recently released for clinical use in this country. We report here a case of nonoliguric acute renal failure associated with zomepirac sodium therapy. This acute renal failure improved upon cessation of zomepirac treatment. Renal biopsy disclosed the presence of a tubulointerstitial nephritis, which was thought to have been responsible for the acute renal failure in this patient. Clinicians should be aware of the potential nephrotoxicity of zomepirac sodium and use caution in its administration, especially in patients with compromised intravascular volume status, hypertension, or preexistent chronic renal disease.

UR - http://www.scopus.com/inward/record.url?scp=0020287237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020287237&partnerID=8YFLogxK

M3 - Article

C2 - 7078269

AN - SCOPUS:0020287237

VL - 57

SP - 351

EP - 354

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 6

ER -